SNPs affecting the clinical outcomes of regularly used immunosuppressants
Recent studies have suggested that genomic diversity may play a key role in different clinical outcomes, and the importance of SNPs is becoming increasingly clear. In this article, we summarize the bioactivity of SNPs that may affect the sensitivity to or possibility of drug reactions that occur among the signaling pathways of regularly used immunosuppressants, such as glucocorticoids, azathioprine, tacrolimus, mycophenolate mofetil, cyclophosphamide and methotrexate. The development of bioinformatics, including machine learning models, has enabled prediction of the proper immunosuppressant dosage with minimal adverse drug reactions for patients after organ transplantation or for those with autoimmune diseases. This article provides a theoretical basis for the personalized use of immunosuppressants in the future.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Pharmacogenomics - 19(2018), 5 vom: 29. Apr., Seite 495-511 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Meng, Huan-Yu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Drug reactions |
|---|
| Anmerkungen: |
Date Completed 13.02.2019 Date Revised 15.02.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/pgs-2017-0182 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM281741255 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM281741255 | ||
| 003 | DE-627 | ||
| 005 | 20231225032332.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/pgs-2017-0182 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0939.xml |
| 035 | |a (DE-627)NLM281741255 | ||
| 035 | |a (NLM)29517418 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Meng, Huan-Yu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SNPs affecting the clinical outcomes of regularly used immunosuppressants |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.02.2019 | ||
| 500 | |a Date Revised 15.02.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Recent studies have suggested that genomic diversity may play a key role in different clinical outcomes, and the importance of SNPs is becoming increasingly clear. In this article, we summarize the bioactivity of SNPs that may affect the sensitivity to or possibility of drug reactions that occur among the signaling pathways of regularly used immunosuppressants, such as glucocorticoids, azathioprine, tacrolimus, mycophenolate mofetil, cyclophosphamide and methotrexate. The development of bioinformatics, including machine learning models, has enabled prediction of the proper immunosuppressant dosage with minimal adverse drug reactions for patients after organ transplantation or for those with autoimmune diseases. This article provides a theoretical basis for the personalized use of immunosuppressants in the future | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a SNPs | |
| 650 | 4 | |a drug reactions | |
| 650 | 4 | |a immunosuppressants | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 700 | 1 | |a Luo, Zhao-Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Wan-Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Cheng-Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Zhi-Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Xue, Yuan-Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Yi-En |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Li-Qun |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Huan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacogenomics |d 2000 |g 19(2018), 5 vom: 29. Apr., Seite 495-511 |w (DE-627)NLM111671396 |x 1744-8042 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2018 |g number:5 |g day:29 |g month:04 |g pages:495-511 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/pgs-2017-0182 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2018 |e 5 |b 29 |c 04 |h 495-511 | ||